The FINANCIAL — Titta joined EBE as acting Executive Director in July 2012 and has since been able to strengthen EBE resources internally and increase added value for EBE’s members.
Prior to EBE, she worked in EFPIA as Director of Communications and before that supporting the Research Directors Group and our IMI project. With 15 years of professional experience in association management and communications, Titta brings to EBE strong entrepreneurial leadership and passion towards global health and life sciences.
Through its active working groups – Biosimilars; Biomanufacturing issues; Rare Diseases & Orphan Medicinal Products; Personalised Medicines and Advanced therapies – all of which are supported by Public Affairs and Regulatory & Technical Affairs committees – EBE brings together experts from 58 biopharmaceutical companies of all sizes. As EFPIA reported, through reinforced collaboration and coordination with EFPIA and its working groups, the EBE team aims to deliver added value to its members.
The Boards of EFPIA and EBE met in June and concluded that the relationship between members is "symbiotic" and that more attention should be given to small and medium sized companies and the conditions under which they operate.
Discussion about this post